5 completed, 1 withdrawn. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
Follow ropsacitinib: new trials by email Literature Review of ropsacitinib trials Research Report on ropsacitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants 14C-PF-06826647-LR 600 mg PO, PF-06826647 600 mg PO, 14C-PF-06826647 100 ug IV - Healthy | Phase 1 | Completed | Pfizer | 6 | 2020-11-10 | 2021-02-21 |
| A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis PF-06826647 100 mg QD, PF-06826647 300 mg QD, PF-06826647 600 mg QD - Ulcerative Colitis | Phase 2 | Withdrawn | Pfizer | 2020-09-30 | 2020-12-17 | |
| A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa PF-06650833, PF-06700841, PF-06826647 - Acne Inversa | Phase 2 | Completed | Pfizer | 194 | 2019-12-02 | 2023-06-15 |
| A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants PF-06826647, Oral Contraceptive (OC) - Healthy | Phase 1 | Completed | Pfizer | 15 | 2019-10-23 | 2020-02-05 |
| A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis PF-06826647 or Placebo, PF-06826647 - Psoriasis | Phase 2 | Completed | Pfizer | 179 | 2019-06-27 | 2021-08-27 |
| A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis PF-06826647 tablet, PF-06826647 oral suspension, Placebo oral solution/suspension - Plaque Psoriasis | Phase 1 | Completed | Pfizer | 109 | 2017-07-14 | 2020-03-31 |
Colitis, Ulcerative (1) · Hidradenitis Suppurativa (1) · Psoriasis (1)
Pfizer (6)
United States (5) · Canada (2) · Australia (1) · Japan (1) · Netherlands (1) · Poland (1)
2018 (1), 2019 (1)